Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
Purpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor (VEGF) (VIBE) surveys. Methods: An online survey of members of VRSI was conducted in July 2018 and January 2020 regarding thei...
Main Authors: | Jay U Sheth, Michael W Stewart, Manoj Khatri, Shashank R Gupta, Shobhit Chawla, Anand Rajendran, Raja Narayanan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Indian Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=2;spage=352;epage=356;aulast=Sheth |
Similar Items
-
A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion
by: Shashikant Sharma, et al.
Published: (2020-07-01) -
Biosimilars in ophthalmology: “Is there a big change on the horizon?”
by: Sharma A, et al.
Published: (2018-10-01) -
Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
by: Lalit Verma, et al.
Published: (2021-01-01) -
Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
by: Shashikant Sharma, et al.
Published: (2021-03-01) -
Clinical effectiveness and safety of razumab (a biosimilar of ranibizumab)
by: Sriram Gopal, et al.
Published: (2020-01-01)